Evidence map›Paper›PMID 40830613›Full record

ArticleScientific reports2025

Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.

Tessa J J de Bitter, Maartje J Geerlings, Leonie I Kroeze, Daniel von Rhein, Milou M F Schuurbiers, Janne M Bibbe, Joyce A M G Smeijers, Hicham Ouchene, Christian Gilissen, Tom G J Hofste and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tessa J J de BitterDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands. Tessa.JJ.debitter@radboudumc.nl.ORCID https://orcid.org/0000-0002-8669-3834
Maartje J GeerlingsDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Leonie I KroezeDepartment of Pathology, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Daniel von RheinDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Milou M F SchuurbiersDepartment of Respiratory Medicine, Radboud university medical center, Nijmegen, The Netherlands.
Janne M BibbeDepartment of Pathology, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Joyce A M G SmeijersDepartment of Pathology, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Hicham OucheneDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Christian GilissenDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Tom G J HofsteDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Marjan M WeissDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Longkankernet
Lisenka E L M VissersDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.
Michel M van den HeuvelDepartment of Respiratory Medicine, Radboud university medical center, Nijmegen, The Netherlands.
Marjolijn J L LigtenbergDepartment of Human Genetics, Radboudumc Research Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands. Marjolijn.Ligtenberg@radboudumc.nl.ORCID https://orcid.org/0000-0003-1290-1474

Funding

AstraZeneca A20-2078Novartis A20-2073Roche diagnostics A21-1351
6 · The paper itself

Abstract

Tumor molecular profiling is essential for therapeutic management of advanced non-small cell lung cancer (NSCLC). However, a biopsy is not for every patient possible and can have complications, which plasma derived circulating tumor DNA (ctDNA) analysis could overcome. We assessed the clinical utility of ctDNA next-generation sequencing (ctDNA-NGS) in 72 NSCLC patients, including 59 who underwent both standard of care (SoC) tissue- or cytology-based genotyping and ctDNA-NGS and 13 who underwent only ctDNA-NGS. Hypothetical shifts in diagnostic yield of a ctDNA-first strategy were modelled using real-world NSCLC molecular testing data from The Netherlands. Concordance between SoC and ctDNA-NGS was 71.2%. In fifteen patients (25.4%) results were discordant, but without direct therapeutic impact. In two patients (3.4%), ctDNA-NGS missed an actionable driver, which would directly impact therapy. Hypothetical shifts in diagnostic yield of a ctDNA-first strategy were determined. This predicted a 7.0% decrease in diagnostic yield for (non-) actionable drivers if all patients underwent ctDNA-NGS, including those currently tested in SoC and those not. Offering ctDNA-NGS only to patients not tested in SoC would increase the diagnostic yield by 6.7%. In conclusion, ctDNA-NGS shows promise for predictive diagnostics in advanced NSCLC, offering added value alongside SoC, but comes with assay-specific and biological challenges.

Indexed as

Carcinoma, Non-Small-Cell LungCirculating Tumor DNAHigh-Throughput Nucleotide SequencingLung NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansLiquid BiopsyMaleMiddle AgedNetherlandsBiomarkers, TumorCirculating Tumor DNAActionable driverCirculating tumor DNAClinical utilityDiagnostic yieldLiquid biopsyNon-small cell lung cancer

Identifiers

PMID40830613
PMCPMC12365262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.